Report Overview: The Global Orphan Drugs Market achieved a valuation of $112.36 Billion in 2022 and is anticipated to exceed $3199.3 Billion by 2030, reflecting a compounded annual growth rate (CAGR) of 7.4% during the forecast period from 2024 to 2032. Key Market Players: RegeneRX Biopharmaceuticals Inc., F.Hoffman-La Roche AG, Pfizer Inc., Shire PLC, AbbVie Inc., Alexion,...